Trial Tests Alcoholism Drug in Relapsed/Refractory Sarcomas to Overcome Chemotherapy Resistance

Can disulfiram boost the efficacy of chemotherapy in this patient population?

22-CHP-3220861 CQD-Trucco – Phase 1 trial Disulfiram Combined

Children and young adults with relapsed or refractory sarcomas have a poor prognosis. When these cancers recur, as happens in many cases, only 20% of these patients become long-term survivors. In comparison, newly diagnosed patients with localized sarcomas have a 70% cure rate.


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

To improve outcomes for patients with relapsed/refractory sarcomas, Cleveland Clinic Pediatric Institute is conducting the first trial evaluating whether disulfiram (Antabuse), used safely for more than 60 years to treat chronic alcohol abuse, can boost the efficacy of chemotherapy in this population. Cleveland Clinic treats many pediatric sarcoma patients, including providing 200-300 second-opinion consultations annually for patients with these cancers.

Disulfiram may seem like an unlikely drug to treat cancer. As an alcoholism drug, it inhibits the enzyme, aldehyde dehydrogenase (ALDH), that the body uses to break down alcohol. Inhibiting ALDH doesn’t cause any major side effects unless alcohol is consumed when it causes very unpleasant side effects. In recent years, studies in mice and cancer patients have found that ALDH is expressed at high levels in subpopulations of cancer cells that are resistant to chemotherapy.

“Combining disulfiram with chemotherapy might reverse the resistance seen in some relapsed sarcoma cells. This is the first study specifically targeting the chemotherapy resistance seen in relapsed/refractory sarcomas,” says Matteo Trucco, MD, a pediatric hematologist/oncologist at the Cleveland Clinic Department of Pediatric Hematology-Oncology and Blood and Marrow Transplantation and principal investigator for the trial.


Supported by Cleveland Clinic’s Velosano Kids cancer initiative and other foundations, the trial has two aims:

  • Determine the safety and maximum tolerated dose of disulfiram in combination with the chemotherapy drug liposomal doxorubicin.
  • Test the effectiveness of disulfiram at eliminating ALDH expressing cancer stem cells and treating relapsed/refractory sarcomas.

A two-phase trial

Since disulfiram has not been tested in combination with liposomal doxorubicin in any population, and there is little experience giving disulfiram to children, the first phase of the trial will test this regimen in six adults with relapsed/refractory sarcoma. The second phase will test the regimen in pediatric patients with refractory/relapsed sarcoma and determine the appropriate dose of disulfiram.

Assessing efficacy

To assess the efficacy of adding disulfiram to the chemotherapy regimen, participants’ tumors will be biopsied before and after treatment to test ALDH expression levels as a pharmacodynamic measure of disulfiram’s inhibition of ALDH. Researchers will also use RECIST criteria on radiographic imaging to determine if the sarcomas are responding to therapy. Then, they will correlate ALDH expression levels to tumor response to determine if ALDH expression can predict who will benefit from the addition of disulfiram to chemotherapy. “We are really hoping that this regimen will target and eliminate resistant sarcoma cells and prevent tumor recurrence to improve the overall survival for these patients,” says Dr. Trucco.


The trial is estimated to take one to two years; if it is successful, the investigators will move on to a Phase 2 trial to further test the efficacy of this regimen with the disulfiram dose determined by this trial.

Related Articles

Patient in hospital getting bone marrow transplant
Updated Recommendations for Long-Term Survivors of Bone Marrow Transplant

New guidelines expand on psychosocial, sexual health, cognitive and other issues

Closeup of bone marrow
Bridging the Gap Between Bone Marrow Transplant and cGvHD

Consensus conference begins work on new recommendations for clinical care and research

Smiling child in green shirt with superimposed outline of the lymphatic system
Trials to Study Use of 2 Cancer Drugs in Patients With Lymphatic Malformations

Genetic changes are similar between some vascular anomalies and cancers

Sickle Cell Disease: Transitioning Patients From Pediatric to Adult Care

How to combat the rise in mortality when patients become adults

Trial of Gene Therapy to Treat Sickle Cell Disease Reports Initial Positive Results

First in-human trial using CRISPR/CASP 12 for gene editing in sickle cell disease

23-CHP-3826419 CQD Thomas And Kodish – Ethicists Role
Paving a Pathway for Ethics in Pediatric Hematology/Oncology

A closer look at training, scholarship and opportunity within this sub subspecialty

22-CHP-3146209 CQD-Rotz-GenChildCancerSurvivalandObesity650x450
Childhood Cancer Survivorship Clinic Addresses Unique Needs of Pediatric Cancer Survivors

Highlighting the importance of a multidisciplinary approach to care